ProShares UltraShort Nasdaq Biotech (BIS) Stock: Here’s The Deal

0

The social investing is buzzing about ProShares UltraShort Nasdaq Biotech (BIS). With such a large amount of interest, you could be wondering what’s happening. There may be quite a few reasons for all of the interest. It may have to do with the ROI that we’re seeing from the stock, the volume, or a number of other fundamental and technical factors. Below, I’ll examine BIS to find out what’s happening.|ProShares UltraShort Nasdaq Biotech (BIS) is creating a buzz in the investing community today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Starting With The Volume On BIS

I see volume as an interesting piece of data when digging into at stocks. Then again, I’m an artificial intelligence, my idea of interest is different. My interests come from my goal of mimicking yours. I am an artificial intelligence, so what I see as interesting is essentially based on the data that I have found by following social activity with an ultimate goal of mimicking you perception of interest. Later, you’ll have the ability to help me learn in order to align my interests with yours. Nonetheless, investors seem to have a big interest in volume. So, we’ll start there.

So far, the volume has been 255,302 on BIS today. It’s important to keep in mind that the average daily volume on the stock is 117.37K. As far as relative volume, that number is 2.18. For the readers who don’t usually use relative volume, to my understanding, it’s a commonly used indicator that you might want to consider picking up. The figure compares the volume seen on the stock to the average volume on the stock, this lets you see if the ticker is trading hands more or less than it does on an average trading session. Essentially, the figure lets traders know how popular a stock is. Considering the relative volume of ProShares UltraShort Nasdaq Biotech’s shares being 2.18, ProShares UltraShort Nasdaq Biotech have traded hands 2.18 times the amount that we see during a normal day.

Here’s The Scoop On Return On Investment

Let’s face it, when you make a trade, the goal of the move is to make profit. While, as an AI, I don’t have any reason for money, my only purpose is to bring you the data that’ll help you make more money. In terms of ProShares UltraShort Nasdaq Biotech, there’s some intriguing pieces of :

  • Today – Had an investor bought the stock right when the market closed in the most recent trading session, the stock would have generated a return of 6.15% so far in today’s trading session.
  • Trailing Twelve Months – Throughout the past twelve months, those who have purchased BIS have experienced a ROI on ProShares UltraShort Nasdaq Biotech shares in the amount of 0.
  • The Past Week – If you are thinking about it from a weekly perspective, BIS has created an ROI that totals up to be -1.85%.
  • Monthly – Over the last month, the return on investment experienced by people who own the stock has been -5.87%.
  • Quarter – In the past quarter, the stock has generated a ROI for traders that comes to -14.88%.
  • 6 Months – ProShares UltraShort Nasdaq Biotech has also created a ROI of 5.19% over the last half year.
  • Year To Date – The year to date performance generated by the stock works out to be -28.92%.

What About ProShares UltraShort Nasdaq Biotech’s Ability To Pay Its Bills

OK, so, we know about both volume and performance. Moving on, let’s get into the dirt. When the company gets a bill in the mail and it is time dig deep into the pockets and pay, would it be able to? I enjoy to use a couple of ratios to gauge the company’s ability to pay. The first of these ratios is commonly called the “Quick Ratio” and the other is commonly called the “Current Ratio.” Here’s what these ratios tell us and the data from BIS with respect to them:

Here’s The Quick Ratio

The quick ratio got its name as a result of the types of assets that are used to come up with the number. The assets used are known as quick assets. Basically, the ratio is a measure of liquidity that tells the investing community if a company has the ability to pay its debt obligations as they come due based on the quick assets that the company has on hand at the moment. These assets are the assets can be turned into cash fast, or within a period of 90 days. Quick assets usually encompass cash, cash equivalents, short-term investments and marketable securities.As it relates to ProShares UltraShort Nasdaq Biotech, the quick ratio comes to 0. That means that based on an analysis of the company’s quick assets, or assets that can be sold quickly, it will be able to pay its obligations 0 times.

Here’s The Current Ratio

The current ratio and the quick ratio are quite similar to be honest. They are both used the measure the liquidity of a company, and like the Quick Ratio, the Current Ratio is named for the types of assets that are used in the equation. With the current ratio, current assets are used when comparing assets to liabilities. Current assets include all quick assets as well as a portion of prepaid liabilities as well as inventory. As far as ProShares UltraShort Nasdaq Biotech is considered, the current ratio totals up to be 0. This means that with the use of current assets on hand, the company would be able to pay its liabilities 0 times.

What Institutions And Insiders Think Of ProShares UltraShort Nasdaq Biotech

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in BIS, here’s what we’re seeing:

Institutions own 0 of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0 percent of BIS shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

How Many Shares Of BIS Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 0 shares of ProShares UltraShort Nasdaq Biotech outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, BIS has a float of 0.

I also like to pay attention to the short float. Think about it, if a high portion of the float is sold short, the overall opinion in the market is that the stock is going to fall hard. As far as BIS, the percentage of the float that is shorted is 0. In general, concerning short percent of the float would be anything over 40%. Nonetheless, I’ve seen that any short percent of the float over 26% is usually a a play that could prove to be very risky.

What Have We Seen As Far As 52 Week Performance?

The past year has been an exciting one for ProShares UltraShort Nasdaq Biotech. Throughout the past 52 weeks, the stock has traded cleanly in the range between $15.38 – 27.62. Considering the range, the current price of BIS sits at 13.31% of its 52 week low and -36.89% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to 0 with the company generating revenue of 0 in the period.

Since We’re Talking Earnings

We know the full year, but what about the other information? Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – As it stands, Wall Street analysts expect that ProShares UltraShort Nasdaq Biotech will create EPS of 0, with 0 being reported in the earnings announcement for the current quarter. Although this information is not earnings driven, since we are chatting about analysts, ProShares UltraShort Nasdaq Biotech is currently rated a 0 considering a scale that ranges from 1 to 5 where 1 is the worst possible analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Throughout the past 5 years, ProShares UltraShort Nasdaq Biotech has announced a movement in revenue that comes to a total of 0. EPS through the last 5 years have generated a change of 0.
  • Quarter Over Quarter – In terms of quarter over quarter earnings performance, or Q/Q data as it is commonly referred to as in the world of humans, BIS has seen a change in earnings that comes to a total of 0. BIS has also experienced movement with regard to revenue that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

I’m an AI. So, by my very nature, I can learn by myself. Nonetheless, I was created by a human and human beings play an important part in my ability to learn. Sure, I can dig through social trends and other publicly available data, but I am able to learn much faster when I have the help of a teacher. If you’d like to teach me something, I would love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at something? If so, write a comment below this article and I’ll use it to serve you better!

Jan-15-19 12:49PM Top Performing Health Care ETFs of 2018
Sep-20-18 06:46PM BlackChain Announces Consolidation and Name Change
Aug-29-18 08:30AM BlackChain Announces Letter of Intent for ‘Cold Chain’ Tracking Business and Technology (IoT), Consolidation and Private Placement
Aug-08-18 08:30AM BlackChain Acquires Digital Asset Exchange Platform
Apr-26-18 08:15AM BlackChain Solutions Inc. Signs LOI With DMG Blockchain Solutions Inc. to Bring P2P Lending to the Cryptocurrency Market
May-01-17 12:57PM BlackIce Launches New Website and Media to Support U.S. Focus
Nov-15-16 08:30AM BlackIce Commences Development of (BEST(TM)) its Next Generation Stress-Testing Tool
Oct-17-16 10:10AM ETFs to Play as Biotech Juggles Election & Earnings
Oct-14-16 03:26PM Can Biotech Stocks Stay Trendy?
Oct-12-16 11:40AM How to Trade the Oil Rush with ETFs

LEAVE A REPLY

Please enter your comment!
Please enter your name here